🔥 Trending Stocks
Most discussed tickers on social platforms within the R3K universe.
| Rank | Company | Price | Change | Sentiment | Earnings |
|---|---|---|---|---|---|
| 1 |  TNXP Tonix Pharmaceuticals Holding Corp | $13.98 | -1.06% | neutral | — |
| 2 |  INOD Innodata Inc | $46.93 | +8.08% | bullish | — |
| 3 |  CRML Critical Metals Corp. | $12.56 | +35.49% | bullish | — |
| 4 |  ARDX Ardelyx Inc | $6.45 | +2.71% | bullish | — |
| 5 |  COST Costco Wholesale Corp | $999.89 | +1.28% | neutral | — |
| 6 |  EBS Emergent Biosolutions Inc | $8.81 | +2.20% | bullish | — |
| 7 |  PFE Pfizer Inc | $27.56 | +1.25% | neutral | — |
| 8 |  OSCR Oscar Health Inc - Ordinary Shares - Class A | $15.79 | +1.02% | neutral | — |
| 9 |  WULF TeraWulf Inc | $20.64 | +6.89% | bullish | — |
| 10 |  CRM Salesforce Inc | $182.14 | +0.51% | neutral | — |
| 11 |  JOBY Joby Aviation Inc | $9.22 | — | neutral | — |
"Tonix Pharmaceuticals is facing significant community backlash as investors express frustration over a potential reverse stock split and ongoing share dilution, despite the company's recent commercial launch of its fibromyalgia treatment and notable insider buying from the CEO. While some retail shareholders are aggressively voting against further dilution, others view the current price as a value opportunity based on growing prescription data and expanding insurance coverage."
"Costco Wholesale is facing heightened scrutiny as the community discusses mixed catalysts, ranging from its robust sales and membership growth to concerns over potential share dilution and its high valuation relative to peers. Market participants are also actively weighing the impact of geopolitical tensions and evolving retail competition against the company's defensive strength, while analysts continue to adjust price targets ahead of upcoming earnings."
"Emergent Biosolutions is trending due to the completion of a strategic debt refinancing with OrbiMed, which extends maturity dates and significantly improves the company's financial flexibility. The community is actively discussing the removal of restrictive debt covenants and the potential for a share price rerate as management shifts focus toward sustainable growth and long-term capital deployment."
"Pfizer is experiencing heightened community debate as investors weigh strong dividend yields and favorable technical setups against ongoing concerns over pipeline growth and regulatory headwinds from potential pharmaceutical tariffs. While some traders are focused on short-term option signals and a possible breakout above key resistance, others remain skeptical, pointing to the company's historical performance and the competitive pressure in the obesity and oncology markets."